

# Feedback plc

## Notice of Results & Investor Presentation

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical technology company, will announce results for the half year ended 30 November 2023 on Wednesday 21 February 2024.

### Analyst Presentation: 09:30, Wednesday 21 February

A remote briefing for analysts will be held at 09:30 on the morning of the results. Analysts interested in attending should contact Walbrook PR on [feedbackplc@walbrookpr.com](mailto:feedbackplc@walbrookpr.com) or 020 7933 8780.

### Investor Presentation: 16:00, Wednesday 21 February

Management will be providing a presentation and hosting an investor Q&A session on the Company's results and future prospects on Wednesday 21 February at 16:00. Investors can sign up for free and register to meet FDBK via the following link: <https://www.investormeetcompany.com/feedback-plc/register-investor>

Investors who have already registered on the Investor Meet Company platform to meet the Company will automatically be invited.

-Ends-

## Enquiries:

### Feedback plc

Tom Oakley, CEO  
Anesh Patel, CFO

+44 (0) 20 3997 7634  
[IR@fbk.com](mailto:IR@fbk.com)

### Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)  
Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

### Walbrook PR Ltd;

Nick Rome/Joe Walker

Tel: 020 7933 8780 or [feedbackplc@walbrookpr.com](mailto:feedbackplc@walbrookpr.com)  
07748 325 236 or 07407 020 470

## About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets

the Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORSSMFSIELSEFE